Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.
about
Atypical antipsychotics for psychosis in adolescentsAtypical antipsychotics for psychosis in adolescentsEscitalopram versus other antidepressive agents for depressionSchizophreniaAripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-AnalysisAdult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion modelLong-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood.Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches.Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents.Neurocognitive decline in early-onset schizophrenia compared with ADHD and normal controls: evidence from a 13-year follow-up study.Practitioner review: schizophrenia spectrum disorders and the at-risk mental state for psychosis in children and adolescents--evidence-based management approaches.Past and present progress in the pharmacologic treatment of schizophrenia.An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia.Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndromeMetabolic syndrome in people with schizophrenia: a review.Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods.Early Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System.Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescentsModifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia.Management of schizophrenia in children and adolescents: focus on pharmacotherapy.Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.Psychotropic drug treatment in anorexia nervosa. Search for differences in efficacy/tolerability between adolescent and mixed-age population.Episodic migraines in children: limited evidence on preventive pharmacological treatments.Do antipsychotics increase diabetes risk in children and adolescents?Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats.Olanzapine versus haloperidol: which can control stuttering better?Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples.Abnormal functional connectivity strength in patients with adolescent-onset schizophrenia: a resting-state fMRI study.Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors.Child and adolescent schizophrenia: pharmacological approachesLong-term effectiveness of electroconvulsive therapy in adolescents with schizophrenia spectrum disorders
P2860
Q24197475-2076F82C-0847-43C1-AF2C-7F85152640BEQ24203954-E2C9B93F-E732-4958-8FB7-F913F2F98ECDQ24241065-F195803F-D081-4B4B-8D25-7D7F85B5365EQ24596536-68DB7ED8-2187-4936-949C-68E8C3476954Q28073540-F2D38566-284A-4DC9-A5AA-18F16CECE45DQ30386851-9EF9368A-EE66-4CAD-BB3A-33F4B29006F0Q30421478-20FA6588-61A9-4783-8EE7-8B6AABB4EB7DQ33533853-E7EFDD37-60B7-468E-A021-F8C0CABF19F2Q33835596-6D046FD6-6718-4068-B3CF-492ECDF2CAEEQ33890155-280A9149-E63B-49AA-B2BC-E1D7856918E1Q34376032-D2483310-E074-4B3F-935A-8181469797BFQ34726953-6FAB9939-CF3C-4483-9C59-9417EAED78D8Q36373454-D6B4418D-C1BE-4036-958D-587C2B08EFCDQ36715883-3C92F7B3-481F-48A7-BFA9-44CD583BA643Q37043479-B130F23D-B2F1-4367-A20E-08762FE55E2AQ37129646-D3905EEE-3573-43B2-AF4B-AFB6EF09EDECQ37244634-94DB7295-79C9-4748-AAC2-977DF6733EA5Q37354917-3E0D153D-8FA3-48B8-A0C8-75356C25D1B5Q37465755-E94F9D24-C08D-47FA-9B81-34E62DB800CAQ37667320-29FD697C-690C-481F-AAAC-AEA7CE2FDD23Q37678423-C4E31A9C-725D-4FC6-BA6B-6317BD945017Q37833061-EB3CE7A5-72FE-499F-8521-69B5328534A0Q38092009-84A0EFF4-205B-4B88-8AD4-3756B0D36E37Q38111696-004A5D15-930E-4C6B-B030-E6A5254AC27DQ38113395-A351BD1A-37C7-4251-823F-59FE96194D61Q38283956-AAE2E6E1-5ECA-4D7E-AA26-7EE0146395C1Q41118486-1278E2A0-317B-435A-8546-5C187EA06CA1Q42148327-44CF18B4-6404-4E5C-ABEC-BD1BD4F4780CQ46122791-32FD85CD-98EA-41AF-981E-3EE88C6DAAF2Q47803215-312EC2B4-F7B7-419F-ADD8-3B245763CF8EQ55431729-54D19AEE-32CD-45F1-A146-E41E78B46D55Q56675062-7C951237-F37C-4921-A136-D52711D07169Q57602623-D0E08E4C-178E-4CEE-AA7F-97A1AB36CF63
P2860
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Efficacy and tolerability of s ...... dolescents with schizophrenia.
@en
type
label
Efficacy and tolerability of s ...... dolescents with schizophrenia.
@en
prefLabel
Efficacy and tolerability of s ...... dolescents with schizophrenia.
@en
P2093
P2860
P921
P356
P1476
Efficacy and tolerability of s ...... dolescents with schizophrenia.
@en
P2093
Joel V Oberstar
Jon M McClellan
Linmarie Sikich
Robert L Findling
S Charles Schulz
Sanjiv Kumra
Sophia Vinogradov
P2860
P356
10.1093/SCHBUL/SBM109
P407
P577
2007-10-08T00:00:00Z
2008-01-01T00:00:00Z